Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd3-MARV
- Development stage
- Phase 2
- Lead developer
- Sabin Vaccine Institute
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**ChAd3-MARV** is a replication-defective chimpanzee adenovirus type 3 (ChAd3)-vectored vaccine expressing the glycoprotein (GP) of the Marburg virus (MARV) Angola strain. Developed by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC), it elicits rapid and durable humoral and cell-mediated immune responses, including GP-specific IgG antibodies, providing 100% protection against lethal MARV challenge in nonhuman primates (NHPs) as early as one week post-single-shot vaccination and lasting up to one year. The vaccine has demonstrated safety and immunogenicity in Phase 1 clinical trials and is advancing to Phase 2 trials supported by BARDA funding, with manufacturing by ReiThera for enhanced stability in a new clinical formulation buffer.[1][3][4][5][9]
- Other names
- ChAd3 Marburg AngolaChAd-3 Marburg AngolaChAd 3 Marburg AngolaChAd3-MARV (Angola) GP
02
Targets
PYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on ChAd3-MARV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd3-MARV.